Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 171

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Mechanisms of action of therapeutic antibodies for cancer

Open access
Redman, J.M., Hill, E.M., AlDeghaither, D., Weiner, L.M.·2015·Molecular Immunology
DOI 10.1016/j.molimm.2015.04.002
Open this paper in CoChat — free account

Abstract

The therapeutic utility of antibodies and their derivatives is achieved by various means. The FDA has approved several targeted antibodies that disrupt signaling of various growth factor receptors for the treatment of a number of cancers. Rituximab, and other anti-CD20 monoclonal antibodies are active in B cell malignancies. As more experience has been gained with anti-CD20 monoclonal antibodies, the multifactorial nature of their anti-tumor mechanisms has emerged. Other targeted antibodies function to dampen inhibitory checkpoints. These checkpoint inhibitors have recently achieved dramatic results in several cancers, including melanoma. These and related antibodies continue to be investigated in the clinical and pre-clinical settings. Novel antibody structures that target two or more antigens have also made their way into clinical use. Tumor targeted antibodies can also be conjugated to chemo- or radiotherapeutic agents, or catalytic toxins, as a means to deliver toxic payloads to cancer cells. Here we provide a review of these mechanisms and a discussion of their relevance to current and future clinical applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molimm.2015.04.002

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 171

Metadata

Authors
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M.
Venue
Molecular Immunology
Publisher
Elsevier BV
Published
2015-10
Volume
67
Issue
2
Pages
28-45
ISSN
0161-5890 (ISSN-L)
DOI
10.1016/j.molimm.2015.04.002
OpenAlex
W2028872374
Cited by
171
References
30
FWCI
10.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of action of therapeutic antibodies for cancer. https://app.cochat.ai/papers/10.1016/j.molimm.2015.04.002
The paper
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015). Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology. https://doi.org/10.1016/j.molimm.2015.04.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.